WANY
STLN

Wealthspire Advisors (New York)’s Starling Oncology STLN Stock Holding History

Wealthspire Advisors (New York)’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.9K Buy
+11,400
New +$47.9K ﹤0.01% 1245
2025
Q4 		– Sell
-3,169
Closed -$11.1K – 2736
2025
Q3 		$11.1K Buy
+3,169
New +$10.9K ﹤0.01% 1969

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wealthspire Advisors (New York)'s STLN Position: Q2 2026 in Review

Wealthspire Advisors (New York) opened a new position in Starling Oncology (STLN) in Q2 2026: 11,400 shares worth $61.9K. The stake represents ﹤0.01% of the portfolio and ranks #1245 among its holdings. This is a return to the name: Wealthspire Advisors (New York) previously reported a position in STLN as recently as Q3 2025.

Wealthspire Advisors (New York) first reported a position in STLN in Q3 2025 and has held it in 2 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Wealthspire Advisors (New York) held 11,400 shares of Starling Oncology worth $61.9K as of Q2 2026.
  • Starling Oncology was a new Wealthspire Advisors (New York) position in Q2 2026.
  • Starling Oncology made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #1245 holding.
  • Wealthspire Advisors (New York) first reported a position in Starling Oncology in Q3 2025 and has held it in 2 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.